Clinical Trials Logo

Anaphylactic Reaction clinical trials

View clinical trials related to Anaphylactic Reaction.

Filter by:
  • None
  • Page 1

NCT ID: NCT06205134 Completed - Anaphylaxis Clinical Trials

Comparative Bioavailability of Intranasal Epinephrine

Start date: August 22, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults

NCT ID: NCT06065137 Not yet recruiting - Hypersensitivity Clinical Trials

Standardised Drug Provocation Testing in Perioperative Hypersensitivity

Start date: October 31, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and outcome of systematic drug provocation testing with anaesthetics at therapeutic doses in adult patients undergoing diagnostic work-up for perioperative hypersensitivity.

NCT ID: NCT06013150 Not yet recruiting - Clinical trials for Anaphylactic Reaction

Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.

Start date: October 23, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1, randomised, double blind placebo controlled 2-part study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled DMC-IH1 (epinephrine) and relative bioavailability and carryover effects of Inhaled (DMC-IH1) and Intramuscular(IM) (EpiPen®) Epinephrine in healthy male and female participants.

NCT ID: NCT05152901 Completed - Clinical trials for Anaphylactic Reaction

Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

Start date: January 6, 2022
Phase: Phase 1
Study type: Interventional

This is a study to determine the relative bioavailability of inhaled epinephrine compared with 0.3mg epinephrine administered IM in healthy male and female participants.

NCT ID: NCT05028257 Recruiting - Vaccine Reaction Clinical Trials

Allergy and COVID-19 Vaccines

COVALL
Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

Prospective monocentric study designed firstly to estimate the proportion of patients who tolerated the continuation of the COVID-19 2nd injection (absence of anaphylactic manifestations). secondly, to know the proportion of definite anaphylactic reactions in cases of suspected anaphylaxis after the first administration of a COVID-19 vaccine the very complete allergological explorations with both the clinical side, skin tests and biological tests will allow us to highlight the responsibility or not of the components of the vaccine,in particular of the excipients (PEG2000, PS80 and tromethamine) in anaphylactic reactions to COVID-19 vaccines A biological collection will be set up during this clinical study in order to study the immunological mechanisms; the effector cells and the signalling pathways involved in these reactions.

NCT ID: NCT03640884 Recruiting - Adverse Drug Event Clinical Trials

Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study

Start date: February 18, 2019
Phase:
Study type: Observational [Patient Registry]

This registry aims to monitor the safety of Xueshuantong Injection and to identify the potential risk factors for the adverse drug reactions.

NCT ID: NCT02559960 Suspended - Adverse Drug Event Clinical Trials

Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study

Start date: September 2015
Phase:
Study type: Observational

This registry aims to monitor the safety of Breviscapine Powder-Injection and to identify the potential risk factors for the adverse drug reactions.